Abstract
The development of selective diacylglycerol kinase alpha (DGKα) inhibitors offers a promising strategy to restore T cell activation and enhance antitumor immunity. Combined with immune checkpoint inhibitors (e.g., PD-1, PD-L1), DGKα inhibitors improve immune response and tumor control, representing a potential breakthrough in cancer immunotherapy.